https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-08-07 / Cancer Cell Int. 2020;20:380
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-08-07 / Cancer Cell Int. 2020;20:3802020-08-07 00:00:002020-08-07 00:00:00Synergy between hemagglutinin 2 (HA2) subunit of influenza fusogenic membrane glycoprotein and oncolytic Newcastle disease virus suppressed tumor growth and further enhanced by Immune checkpoint PD-1 blockade
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-07-07 / Cancers (Basel) 2020 Jul;12(7)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-07-07 / Cancers (Basel) 2020 Jul;12(7)2020-07-07 00:00:002020-07-07 00:00:00Advances in Anti-Cancer Immunotherapy: Car-T Cell, Checkpoint Inhibitors, Dendritic Cell Vaccines, and Oncolytic Viruses, and Emerging Cellular and Molecular Targets
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-07-01 / J Thorac Oncol 2020 Jul;15(7):e111-e113
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-07-01 / J Thorac Oncol 2020 Jul;15(7):e111-e1132020-07-01 00:00:002020-07-01 00:00:00Oncolytic Viral Therapy for Malignant Pleural Mesothelioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-07-01 / Discov Med 2020 Jul-Aug;30(159):39-48
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-07-01 / Discov Med 2020 Jul-Aug;30(159):39-482020-07-01 00:00:002020-07-01 00:00:00Oncolytic therapy and gene therapy for cancer: recent advances in antitumor effects of Newcastle disease virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-06-30 / Expert Rev Anticancer Ther 2020 Aug;20(8):639-646
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-06-30 / Expert Rev Anticancer Ther 2020 Aug;20(8):639-6462020-06-30 00:00:002021-11-15 13:19:48Position paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-06-29 / Cancer Cell Int. 2020;20:278
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-06-29 / Cancer Cell Int. 2020;20:2782020-06-29 00:00:002020-06-29 00:00:00Cytotoxicity study of the interleukin-12-expressing recombinant Newcastle disease virus strain, rAF-IL12, towards CT26 colon cancer cells in vitro and in vivo
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-06-27 / Virusdisease 2020 Sep;31(3):341-348
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-06-27 / Virusdisease 2020 Sep;31(3):341-3482020-06-27 00:00:002020-06-27 00:00:00Newcastle disease virus suppress glycolysis pathway and induce breast cancer cells death
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-06-05 / Cells 2020 Jun;9(6)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-06-05 / Cells 2020 Jun;9(6)2020-06-05 00:00:002020-06-05 00:00:00Newcastle Disease Virus (NDV) Oncolytic Activity in Human Glioma Tumors Is Dependent on CDKN2A-Type I IFN Gene Cluster Codeletion
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-05-19 / Medicines (Basel) 2020 May;7(5)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-05-19 / Medicines (Basel) 2020 May;7(5)2020-05-19 00:00:002021-11-15 20:10:42Addition of Multimodal Immunotherapy to Combination Treatment Strategies for Children with DIPG: A Single Institution Experience
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-05-14 / Gene Ther. 2020 May;
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-05-14 / Gene Ther. 2020 May;2020-05-14 00:00:002020-05-14 00:00:00Optimization of oncolytic effect of Newcastle disease virus Clone30 by selecting sensitive tumor host and constructing more oncolytic viruses
